Author: PharmaSignal News Desk

Novo Nordisk’s semaglutide failed in two Alzheimer’s trials, impacting stock by 10%.

Novo Nordisk Alzheimer’s trial with semaglutide fails to slow disease progression in over 3,800 patients.

Takeda rare disease drug is under FDA investigation following a patient death and reports of neutralizing antibodies.

Biogen Dayra partnership aims to identify oral macrocycle candidates for high-priority immunological targets, enhancing Biogen’s immune portfolio.

QurAlis hires Manoj Malhotra as Chief Medical Officer, leveraging his experience from AbbVie to strengthen its leadership.

FDA priority voucher drug vote excluded review staff, involving top officials in a major procedural shift.

Mark Cuban discusses drug pricing challenges in biotech, highlighting potential impacts on the industry.

Novo Nordisk vision loss compensation awarded to four Danish patients using Wegovy and Ozempic, totaling $123,253.

Recursion leadership change sees Najat Khan taking over as CEO, focusing on AI-driven drug development results.

FDA voucher program raises ethical concerns as experts warn of procedural risks and market impacts.